Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia
Launched by UNIVERSITY HOSPITAL, GRENOBLE · May 2, 2019
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
This is a pilot monocentric, non-randomized, controlled study. The total duration of the project is 24 months. For each patient, the total duration of the study will be one month.
The primary goal is to study gait parameters in patients with focal dystonia (CD and BS) before and after botulinum toxin treatment.
The secondary goal is to study interactions between dystonia severity and gait disorders, if gait disorders are objectified. The investigators will also examine whether botulinum toxin treatment affects gait parameters.
The main dependent variable regarding gait analysis will be g...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • speaking French, in the ability to understand clinical tests and explorations,
- • in ability to move to the CHU Grenoble Alpes
- • Diagnosis of cervical dystonia or isolated Blepharospasm,
- • Absence of neurological or psychiatric disorders,
- • Affiliation to a health insurance,
- • Signed consent fo the subject.
- Exclusion Criteria:
- • Pregnant women (positive pregnancy test), parturient or breastfeeding
- • Cervical dystonia or Blepharospasm of secondary origin
- • subjects having benefited from deep brain stimulation,
- • History of other pathologies that may lead to walking disorders, inability to walk without technical assistance, inability to walk for more than 10 minutes,
- • Subjects receiving botulinum toxin treatment for another cause.
- Prohibited treatments and procedures:
- • Antecedent of pathologies that may cause walking disorders
- • Simultaneous participation in another Interventional study
- • Subject in time of exclusion from another study
- • Subject under guardianship or having curators (major protected)
- • Subject under administrative or judicial supervision
- • Subject not able to be contacted in case of emergency
About University Hospital, Grenoble
The University Hospital of Grenoble is a leading academic medical center dedicated to advancing healthcare through innovative clinical research and comprehensive patient care. As a prominent sponsor of clinical trials, the hospital leverages its expertise in various medical disciplines to facilitate cutting-edge studies that aim to improve treatment outcomes and enhance patient safety. With a strong commitment to collaboration, the University Hospital of Grenoble engages in partnerships with academic institutions, industry leaders, and regulatory bodies to drive scientific discovery and translate research findings into clinical practice. Its state-of-the-art facilities and multidisciplinary teams ensure rigorous adherence to ethical standards and regulatory guidelines, fostering an environment where groundbreaking research can thrive.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
La Tronche, Isere, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials